{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:09:09Z","timestamp":1790762949882,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-24828"],"award-info":[{"award-number":["IG-24828"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Italy Post-Doc ID 31210-2024"],"award-info":[{"award-number":["Italy Post-Doc ID 31210-2024"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022XPF8A5"],"award-info":[{"award-number":["2022XPF8A5"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is a leading cause of cancer-related mortality, largely driven by aberrant activation of the WNT\/\u03b2-catenin and RAS pathways. Despite recent therapeutic advances, effective strategies to target these oncogenic signals remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A multi-step chemical library screen was performed to identify compounds capable of suppressing \u03b2-catenin and RAS signaling. Drug mechanisms and combination effects were investigated through functional assays, in vitro and in vivo experiments, and transcriptomic profiling. Survival analysis of the Sidra-LUMC AC-ICAM CRC cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009303) was conducted to evaluate the prognostic significance of candidate target genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified the CDK4\/6 inhibitor palbociclib as an unexpected suppressor of \u03b2-catenin signaling. Uniquely, palbociclib promoted GSK3\u03b2-mediated \u03b2-catenin degradation by dampening AKT activity, revealing a previously unrecognized mechanism of action and broadening its role beyond canonical cell-cycle inhibition. Building on this mechanism, we found that combining palbociclib with the KRAS\n                      <jats:sup>G12D<\/jats:sup>\n                      -specific inhibitor MRTX1133 elicited potent and selective anti-tumor effects in vitro and in vivo. Parallel screening also revealed the ERK5 inhibitor ERK5-IN-1 as a promising combination partner: co-administration with palbociclib strongly suppressed proliferation across multiple CRC models, showed minimal toxicity in normal cells, and produced durable tumor control in vivo. Transcriptomic profiling indicated that both combinations converge on a common program of cancer cell-state reprogramming, characterized by suppression of proliferative drivers and remodeling of metabolic and mitochondrial pathways. Underscoring the clinical relevance of our findings, survival analysis of the Sidra-LUMC AC-ICAM CRC cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009303) revealed that ERK5 target genes\n                      <jats:italic>CREB5<\/jats:italic>\n                      and\n                      <jats:italic>NUPR1<\/jats:italic>\n                      , identified in our dataset, were consistently linked to poor prognosis, thereby connecting this signaling axis to unfavorable patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Together, these findings position palbociclib as a versatile therapeutic backbone in CRC. By simultaneously targeting cell cycle and oncogenic signaling networks, palbociclib-based combinations induce synergistic and durable responses, offering a compelling rationale for tailored therapeutic strategies in molecularly defined CRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08420-7","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T09:14:08Z","timestamp":1781860448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Palbociclib targets \u03b2-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-642X","authenticated-orcid":false,"given":"Matteo","family":"Villa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2492-8974","authenticated-orcid":false,"given":"Federica","family":"Malighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7757-7365","authenticated-orcid":false,"given":"Alberto Maria","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3227-8280","authenticated-orcid":false,"given":"Nicoletta","family":"Cordani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3428-5353","authenticated-orcid":false,"given":"Andrea","family":"Aroldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8074-2308","authenticated-orcid":false,"given":"Alfonso","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6087-2666","authenticated-orcid":false,"given":"Daniele","family":"Ramazzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-5149","authenticated-orcid":false,"given":"Luca","family":"Mologni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"10","key":"8420_CR1","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174.","journal-title":"Transl Oncol"},{"issue":"1","key":"8420_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/gr1239","volume":"13","author":"M Ahmed","year":"2020","unstructured":"Ahmed M. Colon Cancer: A Clinician\u2019s Perspective in 2019. Gastroenterol Res. 2020;13(1):1\u201310.","journal-title":"Gastroenterol Res"},{"key":"8420_CR3","doi-asserted-by":"crossref","unstructured":"Hatano Y, Fukuda S, Hisamatsu K, Hirata A, Hara A, Tomita H. Multifaceted interpretation of colon cancer stem cells. Int J Mol Sci. 2017;18(7).","DOI":"10.3390\/ijms18071446"},{"key":"8420_CR4","doi-asserted-by":"crossref","unstructured":"Alrushaid N, Khan FA, Al-Suhaimi E, Elaissari A. Progress and perspectives in colon cancer pathology, diagnosis, and treatments. Diseases. 2023;11(4).","DOI":"10.3390\/diseases11040148"},{"key":"8420_CR5","doi-asserted-by":"crossref","unstructured":"M\u00e1rmol I, S\u00e1nchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1).","DOI":"10.3390\/ijms18010197"},{"issue":"2","key":"8420_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/molecules21020169","volume":"21","author":"S Afrin","year":"2016","unstructured":"Afrin S, Giampieri F, Gasparrini M, Forbes-Hernandez TY, Varela-L\u00f3pez A, Quiles JL, et al. Chemopreventive and Therapeutic Effects of Edible Berries: A Focus on Colon Cancer Prevention and Treatment. Molecules. 2016;21(2):169.","journal-title":"Molecules"},{"key":"8420_CR7","doi-asserted-by":"crossref","unstructured":"Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: dysregulated signaling pathways (Review). Int J Mol Med. 2021;47(3).","DOI":"10.3892\/ijmm.2021.4847"},{"issue":"11\u201312","key":"8420_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1101\/gad.348226.120","volume":"35","author":"J Li","year":"2021","unstructured":"Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35(11\u201312):787\u2013820.","journal-title":"Genes Dev"},{"issue":"23","key":"8420_CR9","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.3748\/wjg.v20.i23.7137","volume":"20","author":"L Sabatino","year":"2014","unstructured":"Sabatino L, Pancione M, Votino C, Colangelo T, Lupo A, Novellino E, et al. Emerging role of the \u03b2-catenin-PPAR\u03b3 axis in the pathogenesis of colorectal cancer. World J Gastroenterol. 2014;20(23):7137\u201351.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"8420_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"8420_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12943-022-01616-7","volume":"21","author":"H Zhao","year":"2022","unstructured":"Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21(1):144.","journal-title":"Mol Cancer"},{"issue":"6","key":"8420_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1517\/14728222.2014.906580","volume":"18","author":"A Sebio","year":"2014","unstructured":"Sebio A, Kahn M, Lenz HJ. The potential of targeting Wnt\/\u03b2-catenin in colon cancer. Expert Opin Ther Targets. 2014;18(6):611\u20135.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"8420_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","volume":"20","author":"G Zhu","year":"2021","unstructured":"Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1):143.","journal-title":"Mol Cancer"},{"key":"8420_CR14","doi-asserted-by":"crossref","unstructured":"Bteich F, Mohammadi M, Li T, Bhat MA, Sofianidi A, Wei N, et al. Targeting KRAS in colorectal cancer: a bench to bedside review. Int J Mol Sci. 2023;24(15).","DOI":"10.3390\/ijms241512030"},{"issue":"1","key":"8420_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.","journal-title":"Signal Transduct Target Ther"},{"key":"8420_CR16","doi-asserted-by":"crossref","unstructured":"Tatli O, Dinler Doganay G. Recent developments in targeting RAS downstream effectors for RAS-driven cancer therapy. Molecules. 2021;26(24).","DOI":"10.3390\/molecules26247561"},{"issue":"5853","key":"8420_CR17","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1126\/science.1145720","volume":"318","author":"LD Wood","year":"2007","unstructured":"Wood LD, Parsons DW, Jones S, Lin J, Sj\u00f6blom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108\u201313.","journal-title":"Science"},{"issue":"7407","key":"8420_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"CGA Network","year":"2012","unstructured":"Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330\u20137.","journal-title":"Nature"},{"issue":"18","key":"8420_CR19","doi-asserted-by":"publisher","first-page":"7253","DOI":"10.1158\/0008-5472.CAN-10-1108","volume":"70","author":"L Mologni","year":"2010","unstructured":"Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, et al. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res. 2010;70(18):7253\u201363.","journal-title":"Cancer Res"},{"issue":"12","key":"8420_CR20","doi-asserted-by":"publisher","first-page":"e51449","DOI":"10.1371\/journal.pone.0051449","volume":"7","author":"L Mologni","year":"2012","unstructured":"Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C. Synergistic effects of combined Wnt\/KRAS inhibition in colorectal cancer cells. PLoS ONE. 2012;7(12):e51449.","journal-title":"PLoS ONE"},{"issue":"17","key":"8420_CR21","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1073\/pnas.0501535102","volume":"102","author":"M Yang","year":"2005","unstructured":"Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway. Proc Natl Acad Sci U S A. 2005;102(17):6027\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"8420_CR22","doi-asserted-by":"publisher","first-page":"10330","DOI":"10.1073\/pnas.94.19.10330","volume":"94","author":"M Ilyas","year":"1997","unstructured":"Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A. 1997;94(19):10330\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8420_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/hmg\/ddn338","volume":"18","author":"EM Kohler","year":"2009","unstructured":"Kohler EM, Chandra SH, Behrens J, Schneikert J. Beta-catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours. Hum Mol Genet. 2009;18(2):213\u201326.","journal-title":"Hum Mol Genet"},{"issue":"36","key":"8420_CR24","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1038\/sj.onc.1204611","volume":"20","author":"J Gayet","year":"2001","unstructured":"Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene. 2001;20(36):5025\u201332.","journal-title":"Oncogene"},{"issue":"14","key":"8420_CR25","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","volume":"70","author":"M Janakiraman","year":"2010","unstructured":"Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010;70(14):5901\u201311.","journal-title":"Cancer Res"},{"issue":"12","key":"8420_CR26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"Web Server issu","key":"8420_CR27","doi-asserted-by":"publisher","first-page":"W77","DOI":"10.1093\/nar\/gkt439","volume":"41","author":"J Wang","year":"2013","unstructured":"Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41(Web Server issue):W77\u201383.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"8420_CR28","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1021\/acschembio.7b00638","volume":"13","author":"J Wang","year":"2018","unstructured":"Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Mu\u00f1oz-Guardiola P, et al. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol. 2018;13(9):2438\u201348.","journal-title":"ACS Chem Biol"},{"key":"8420_CR29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ejmech.2013.10.052","volume":"70","author":"X Deng","year":"2013","unstructured":"Deng X, Elkins JM, Zhang J, Yang Q, Erazo T, Gomez N, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758\u201367.","journal-title":"Eur J Med Chem"},{"key":"8420_CR30","doi-asserted-by":"crossref","unstructured":"Cogliati V, Capici S, Pepe FF, di Mauro P, Riva F, Cicchiello F, et al. How to treat HR+\/HER2- metastatic breast cancer patients after CDK4\/6 inhibitors: an unfinished story. Life (Basel). 2022;12(3).","DOI":"10.3390\/life12030378"},{"key":"8420_CR31","doi-asserted-by":"crossref","unstructured":"Cordani N, Mologni L, Piazza R, Tettamanti P, Cogliati V, Mauri M, et al. TWIST1 upregulation is a potential target for reversing resistance to the CDK4\/6 inhibitor in metastatic luminal breast cancer cells. Int J Mol Sci. 2023;24(22).","DOI":"10.3390\/ijms242216294"},{"issue":"1","key":"8420_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12609-017-0232-0","volume":"9","author":"AC Garrido-Castro","year":"2017","unstructured":"Garrido-Castro AC, Goel S. CDK4\/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. Curr Breast Cancer Rep. 2017;9(1):26\u201333.","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"8420_CR33","doi-asserted-by":"publisher","first-page":"19319","DOI":"10.1038\/s41598-025-04008-1","volume":"15","author":"HM Sleem","year":"2025","unstructured":"Sleem HM, Ali AA, Ramadan E. Cisplatin palbociclib combination differentially modulates PTEN AKT signaling via Hsp90 in hepatocellular carcinoma cells. Sci Rep. 2025;15(1):19319.","journal-title":"Sci Rep"},{"issue":"1","key":"8420_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/jcb.29249","volume":"121","author":"O Rencuzogullar\u0131","year":"2020","unstructured":"Rencuzogullar\u0131 O, Yerlikaya PO, G\u00fcrkan A, Ar\u0131san ED, Telci D. Palbociclib, a selective CDK4\/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells. J Cell Biochem. 2020;121(1):508\u201323.","journal-title":"J Cell Biochem"},{"issue":"12","key":"8420_CR35","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.18632\/aging.101356","volume":"9","author":"D Hadjadj","year":"2017","unstructured":"Hadjadj D, Kim SJ, Denecker T, Ben Driss L, Cadoret JC, Maric C, et al. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas. Aging. 2017;9(12):2695\u2013716.","journal-title":"Aging"},{"issue":"14","key":"8420_CR36","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1182\/blood.2023021349","volume":"143","author":"I Crespiatico","year":"2024","unstructured":"Crespiatico I, Zaghi M, Mastini C, D\u2019Aliberti D, Mauri M, Mercado CM, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399\u2013413.","journal-title":"Blood"},{"key":"8420_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers14194840","volume":"14","author":"M Lepore Signorile","year":"2022","unstructured":"Lepore Signorile M, Grossi V, Fasano C, Forte G, Disciglio V, Sanese P, et al. c-MYC Protein Stability Is Sustained by MAPKs in Colorectal Cancer. Cancers (Basel). 2022;14:19.","journal-title":"Cancers (Basel)"},{"key":"8420_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnmol.2011.00040","volume":"4","author":"O Kaidanovich-Beilin","year":"2011","unstructured":"Kaidanovich-Beilin O, Woodgett JR. GSK-3: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci. 2011;4:40.","journal-title":"Front Mol Neurosci"},{"issue":"1\u20132","key":"8420_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11010-011-0965-4","volume":"356","author":"DP Ponce","year":"2011","unstructured":"Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E, et al. CK2 functionally interacts with AKT\/PKB to promote the \u03b2-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem. 2011;356(1\u20132):127\u201332.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"8420_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/cas.13931","volume":"110","author":"JS Chen","year":"2019","unstructured":"Chen JS, Huang JQ, Luo B, Dong SH, Wang RC, Jiang ZK, et al. PIK3CD induces cell growth and invasion by activating AKT\/GSK-3\u03b2\/\u03b2-catenin signaling in colorectal cancer. Cancer Sci. 2019;110(3):997\u20131011.","journal-title":"Cancer Sci"},{"issue":"38","key":"8420_CR41","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1021\/acs.biochem.6b00629","volume":"55","author":"TK Nomanbhoy","year":"2016","unstructured":"Nomanbhoy TK, Sharma G, Brown H, Wu J, Aban A, Vogeti S, et al. Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response. Biochemistry. 2016;55(38):5434\u201341.","journal-title":"Biochemistry"},{"issue":"12","key":"8420_CR42","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1021\/acschembio.5b00368","volume":"10","author":"NJ Sumi","year":"2015","unstructured":"Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4\/6 Inhibitors in Lung Cancer. ACS Chem Biol. 2015;10(12):2680\u20136.","journal-title":"ACS Chem Biol"},{"issue":"4","key":"8420_CR43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1021\/acsmedchemlett.2c00530","volume":"14","author":"ZW Davis-Gilbert","year":"2023","unstructured":"Davis-Gilbert ZW, Kr\u00e4mer A, Dunford JE, Howell S, Senbabaoglu F, Wells CI, et al. Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2. ACS Med Chem Lett. 2023;14(4):432\u201341.","journal-title":"ACS Med Chem Lett"},{"key":"8420_CR44","doi-asserted-by":"publisher","first-page":"115331","DOI":"10.1016\/j.ejmech.2023.115331","volume":"254","author":"R Mazzucato","year":"2023","unstructured":"Mazzucato R, Roberti M, Capelli AM, Rancati F, Biagetti M, Fiorelli C, et al. Application of an inhalation by design approach to the identification and in-vitro evaluation of novel purine based PI3K\u03b4 inhibitors. Eur J Med Chem. 2023;254:115331.","journal-title":"Eur J Med Chem"},{"issue":"39","key":"8420_CR45","doi-asserted-by":"publisher","first-page":"41736","DOI":"10.18632\/oncotarget.6153","volume":"6","author":"A Cheraghchi-Bashi","year":"2015","unstructured":"Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, et al. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget. 2015;6(39):41736\u201349.","journal-title":"Oncotarget"},{"issue":"6","key":"8420_CR46","doi-asserted-by":"publisher","first-page":"e100880","DOI":"10.1371\/journal.pone.0100880","volume":"9","author":"M Dumble","year":"2014","unstructured":"Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE. 2014;9(6):e100880.","journal-title":"PLoS ONE"},{"issue":"1","key":"8420_CR47","first-page":"39","volume":"9","author":"Z Sirhan","year":"2022","unstructured":"Sirhan Z, Thyagarajan A, Sahu RP. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Mil Med Res. 2022;9(1):39.","journal-title":"Mil Med Res"},{"issue":"7","key":"8420_CR48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597\u2013609.","journal-title":"N Engl J Med"},{"issue":"6","key":"8420_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024;14(6):994\u20131017.","journal-title":"Cancer Discov"},{"issue":"12","key":"8420_CR50","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.cellsig.2012.08.001","volume":"24","author":"D Perez-Madrigal","year":"2012","unstructured":"Perez-Madrigal D, Finegan KG, Paramo B, Tournier C. The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). Cell Signal. 2012;24(12):2360\u20138.","journal-title":"Cell Signal"},{"issue":"1","key":"8420_CR51","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41467-020-15031-3","volume":"11","author":"PA Lochhead","year":"2020","unstructured":"Lochhead PA, Tucker JA, Tatum NJ, Wang J, Oxley D, Kidger AM, et al. Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nat Commun. 2020;11(1):1383.","journal-title":"Nat Commun"},{"issue":"34","key":"8420_CR52","doi-asserted-by":"publisher","first-page":"26199","DOI":"10.1074\/jbc.M110.103127","volume":"285","author":"N Ohnesorge","year":"2010","unstructured":"Ohnesorge N, Viemann D, Schmidt N, Czymai T, Spiering D, Schmolke M, et al. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). J Biol Chem. 2010;285(34):26199\u2013210.","journal-title":"J Biol Chem"},{"issue":"5","key":"8420_CR53","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41591-023-02324-5","volume":"29","author":"J Roelands","year":"2023","unstructured":"Roelands J, Kuppen PJK, Ahmed EI, Mall R, Masoodi T, Singh P, et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat Med. 2023;29(5):1273\u201386.","journal-title":"Nat Med"},{"issue":"1","key":"8420_CR54","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13046-020-01673-0","volume":"39","author":"S Wang","year":"2020","unstructured":"Wang S, Qiu J, Liu L, Su C, Qi L, Huang C, et al. CREB5 promotes invasiveness and metastasis in colorectal cancer by directly activating MET. J Exp Clin Cancer Res. 2020;39(1):168.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"8420_CR55","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.18632\/aging.203012","volume":"13","author":"W He","year":"2021","unstructured":"He W, Cheng F, Zheng B, Wang J, Zhao G, Yao Z, et al. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN\/AKT\/mTOR pathway. Aging. 2021;13(10):14015\u201338.","journal-title":"Aging"},{"issue":"3","key":"8420_CR56","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/dna.2019.5196","volume":"39","author":"A Li","year":"2020","unstructured":"Li A, Li X, Chen X, Zeng C, Wang Z, Li Z, et al. NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K\/AKT\/mTOR Pathway. DNA Cell Biol. 2020;39(3):368\u201378.","journal-title":"DNA Cell Biol"},{"issue":"6","key":"8420_CR57","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/jpp\/rgab010","volume":"73","author":"L Jiang","year":"2021","unstructured":"Jiang L, Wang W, Li Z, Zhao Y, Qin Z. NUPR1 participates in YAP-mediate gastric cancer malignancy and drug resistance via AKT and p21 activation. J Pharm Pharmacol. 2021;73(6):740\u20138.","journal-title":"J Pharm Pharmacol"},{"key":"8420_CR58","doi-asserted-by":"publisher","first-page":"659260","DOI":"10.3389\/fcell.2021.659260","volume":"9","author":"X Shu","year":"2021","unstructured":"Shu X, Zhan PP, Sun LX, Yu L, Liu J, Sun LC, et al. BCAT1 Activates PI3K\/AKT\/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer. Front Cell Dev Biol. 2021;9:659260.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"8420_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10735-022-10108-3","volume":"54","author":"Y Ding","year":"2023","unstructured":"Ding Y, Wang X, Lu S, Lai A, Xie B, He X, et al. BCAT1, as a prognostic factor for HCC, can promote the development of liver cancer through activation of the AKT signaling pathway and EMT. J Mol Histol. 2023;54(1):25\u201339.","journal-title":"J Mol Histol"},{"issue":"2","key":"8420_CR60","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/odi.15084","volume":"31","author":"Z Yuan","year":"2025","unstructured":"Yuan Z, Li M, Tang Z. BCAT1 promotes cell proliferation, migration, and invasion via the PI3K-Akt signaling pathway in oral squamous cell carcinoma. Oral Dis. 2025;31(2):364\u201375.","journal-title":"Oral Dis"},{"issue":"1","key":"8420_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12967-024-04970-w","volume":"22","author":"H You","year":"2024","unstructured":"You H, Song G, Xu Z, Chen S, Shen W, Liu H, et al. HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1. J Transl Med. 2024;22(1):178.","journal-title":"J Transl Med"},{"issue":"1","key":"8420_CR62","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13578-023-01185-2","volume":"13","author":"M Palma","year":"2023","unstructured":"Palma M, Riffo E, Farias A, Coliboro-Dannich V, Espinoza-Francine L, Escalona E, et al. NUAK1 coordinates growth factor-dependent activation of mTORC2 and Akt signaling. Cell Biosci. 2023;13(1):232.","journal-title":"Cell Biosci"},{"key":"8420_CR63","doi-asserted-by":"crossref","unstructured":"Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, et al. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS ONE. 2010;5(10).","DOI":"10.1371\/journal.pone.0013091"},{"issue":"16","key":"8420_CR64","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/bph.16080","volume":"180","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Tseng HH, Wang YH, Fang SY, Chen SH, Chen CH, et al. Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis. Br J Pharmacol. 2023;180(16):2172\u201388.","journal-title":"Br J Pharmacol"},{"issue":"17","key":"8420_CR65","first-page":"5234","volume":"63","author":"Z Wang","year":"2003","unstructured":"Wang Z, Vogelstein B, Kinzler KW. Phosphorylation of beta-catenin at S33, S37, or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. Cancer Res. 2003;63(17):5234\u20135.","journal-title":"Cancer Res"},{"key":"8420_CR66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biochi.2018.11.003","volume":"157","author":"AS Aghabozorgi","year":"2019","unstructured":"Aghabozorgi AS, Bahreyni A, Soleimani A, Bahrami A, Khazaei M, Ferns GA, et al. Role of adenomatous polyposis coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie. 2019;157:64\u201371.","journal-title":"Biochimie"},{"key":"8420_CR67","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41420-019-0150-1","volume":"5","author":"DM Pereira","year":"2019","unstructured":"Pereira DM, Gomes SE, Borralho PM, Rodrigues CMP. MEK5\/ERK5 activation regulates colon cancer stem-like cell properties. Cell Death Discov. 2019;5:68.","journal-title":"Cell Death Discov"},{"issue":"4","key":"8420_CR68","doi-asserted-by":"publisher","first-page":"e1718","DOI":"10.1038\/cddis.2015.83","volume":"6","author":"AE Sim\u00f5es","year":"2015","unstructured":"Sim\u00f5es AE, Pereira DM, Gomes SE, Brito H, Carvalho T, French A, et al. Aberrant MEK5\/ERK5 signalling contributes to human colon cancer progression via NF-\u03baB activation. Cell Death Dis. 2015;6(4):e1718.","journal-title":"Cell Death Dis"},{"issue":"23","key":"8420_CR69","doi-asserted-by":"publisher","first-page":"34322","DOI":"10.18632\/oncotarget.9107","volume":"7","author":"DM Pereira","year":"2016","unstructured":"Pereira DM, Sim\u00f5es AE, Gomes SE, Castro RE, Carvalho T, Rodrigues CM, et al. MEK5\/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget. 2016;7(23):34322\u201340.","journal-title":"Oncotarget"},{"issue":"21","key":"8420_CR70","doi-asserted-by":"publisher","first-page":"15772","DOI":"10.1021\/acs.jmedchem.1c01096","volume":"64","author":"RM Karim","year":"2021","unstructured":"Karim RM, Bikowitz MJ, Chan A, Zhu JY, Grassie D, Becker A, et al. Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors. J Med Chem. 2021;64(21):15772\u201386.","journal-title":"J Med Chem"},{"key":"8420_CR71","doi-asserted-by":"publisher","first-page":"1526676","DOI":"10.3389\/fcvm.2025.1526676","volume":"12","author":"VSK Samanthapudi","year":"2025","unstructured":"Samanthapudi VSK, Kotla S, Le NT. TNIK-driven regulation of ERK5 transcriptional activity in endothelial cells. Front Cardiovasc Med. 2025;12:1526676.","journal-title":"Front Cardiovasc Med"},{"key":"8420_CR72","doi-asserted-by":"crossref","unstructured":"Huang J, Zheng L, Sun Z, Li J. CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review). Int J Mol Med. 2022;50(4).","DOI":"10.3892\/ijmm.2022.5184"},{"issue":"Pt 1","key":"8420_CR73","doi-asserted-by":"publisher","first-page":"133872","DOI":"10.1016\/j.ijbiomac.2024.133872","volume":"276","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, Bano N, Khanna K, Gupta D, Raza K. Reporting multitargeted potency of Tiaprofenic acid against lung cancer: Molecular fingerprinting, MD simulation, and MTT-based cell viability assay studies. Int J Biol Macromol. 2024;276(Pt 1):133872.","journal-title":"Int J Biol Macromol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08420-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08420-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08420-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:02:35Z","timestamp":1788397355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08420-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8420"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08420-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mice were maintained under standard housing conditions, in accordance with institutional guidelines and protocols approved by the University of Milano-Bicocca Ethical Committee for Animal Welfare and the Italian Ministry of Health.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1132"}}